Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial.

Gautschi O, Park K, Solomon BJ, Tomasini P, Loong HH, De Braud F, Goto K, Peterson P, Barker S, Liming K, Oxnard GR, Frimodt-Moller B, Drilon A

Open source

DOI
10.1200/jco-24-02076
Published
2025 May 20
Container
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1200/jco-24-02076,
  title = {Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial.},
  author = {Gautschi O and Park K and Solomon BJ and Tomasini P and Loong HH and De Braud F and Goto K and Peterson P and Barker S and Liming K and Oxnard GR and Frimodt-Moller B and Drilon A},
  year = {2025},
  journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  doi = {10.1200/jco-24-02076},
  url = {https://doi.org/10.1200/jco-24-02076}
}

RIS

TY  - JOUR
TI  - Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial.
AU  - Gautschi O
AU  - Park K
AU  - Solomon BJ
AU  - Tomasini P
AU  - Loong HH
AU  - De Braud F
AU  - Goto K
AU  - Peterson P
AU  - Barker S
AU  - Liming K
AU  - Oxnard GR
AU  - Frimodt-Moller B
AU  - Drilon A
PY  - 2025
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DO  - 10.1200/jco-24-02076
UR  - https://doi.org/10.1200/jco-24-02076
ER  - 

APA

O, G., K, P., BJ, S., P, T., HH, L., F, D. B., K, G., P, P., S, B., K, L., GR, O., B, F., & A, D. (2025). Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco-24-02076

Source records